STOCK TITAN

IBIO Stock News

IBIO NASDAQ

iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.

Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.

Rhea-AI Summary

iBio (IBIO) reported extended preclinical findings for its IBIO-610 antibody candidate and animal data from its amylin program.

In obese non-human primates, IBIO-610 produced a 2.3% vehicle-adjusted reduction in body weight from baseline at week 28. At week 24, total body fat was 9.6% lower, abdominal subcutaneous fat 16.6% lower and visceral fat 10.96% lower than vehicle; lean mass was generally maintained. Near-complete suppression of active Activin E persisted through week 28. The study included five treated animals and six vehicle controls; dosing was initially every eight weeks, followed by more frequent dosing and a dose-free period.

The amylin antibody-peptide fusion selectively activated amylin receptors 1 and 3 in laboratory testing and reduced food intake over 24 hours in a single-dose lean-rat study versus vehicle. iBio plans further preclinical studies in diet-induced obesity models.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.86%
Tags
none
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) reported higher revenue and a wider net loss for its fiscal first quarter ended September 30, 2026. Revenue rose to $1.075 million from $100,000 a year earlier, while net loss widened to $7.551 million from $5.720 million. Loss per share narrowed to $0.05 from $0.11. Cash, cash equivalents and debt investments totaled approximately $76.7 million.

iBio completed single ascending dose testing of IBIO-600; it anticipates interim data and the start of multiple ascending dose testing in the first quarter of 2027. In obese non-human primates at week eight, fat represented 93% of weight lost with IBIO-610 plus semaglutide versus 77% with semaglutide alone; lean mass represented 6% versus 22%. The company targets an IBIO-610 IND-equivalent filing, seeking permission for human testing, by year-end 2026 and first-in-human studies in the first half of 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.67%
Tags
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) will participate in three investor conferences in November and December 2026, with executives available for one-on-one meetings.

CEO and Chief Scientific Officer Martin Brenner and CFO Felipe Duran will participate. Fireside chats are scheduled at Guggenheim on November 10 at 9:00 a.m. ET and Piper Sandler on December 1 at 9:30–9:55 a.m. ET. Jefferies meetings run November 16–19 in London.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.95%
Tags
conferences
Rhea-AI Summary

iBio (IBIO) highlighted preclinical data showing a lower lean-mass share of weight loss when IBIO-610 was combined with semaglutide.

In an eight-week obese non-human primate study with six animals per group, lean mass accounted for 6% of weight lost with the combination, versus 22% with semaglutide alone. At week 8, fat accounted for 93% of weight lost with a single IBIO-610 dose alongside twice-weekly semaglutide, compared with 77% for semaglutide alone. Previously reported results showed a 97% reduction in serum levels of active Activin E, the antibody's target, at week 8 following one intravenous dose. iBio expects to begin first-in-human trials in the first half of 2027. The data were discussed at the EASD Annual Meeting on October 1, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.44%
Tags
none
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) announced it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8–10, 2026. CEO and Chief Scientific Officer Martin Brenner will join a fireside chat on September 8 at 4:30 p.m. ET, available via livestream and 90-day webcast replay on iBio’s Investor Relations site.

CFO Felipe Duran will join Dr. Brenner for one-on-one investor meetings during the conference, which can be requested by contacting the company’s investor relations email. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) reported fiscal year 2026 results and a corporate update, highlighted by its transition to a clinical-stage company with the Phase 1 trial of IBIO-600, a long-acting anti-myostatin antibody. The single ascending dose phase dosed 31 of 32 participants across four cohorts with no safety findings that prevented dose escalation, and iBio is preparing multiple ascending dose escalation.

The company advanced obesity and cardiometabolic candidates IBIO-610 into IND-enabling studies and IBIO-800 into IND-enabling development, and in-licensed AstralBio’s amylin receptor antibody program. iBio closed an August 2025 public offering with potential gross proceeds up to $100 million and a $26 million private placement in January 2026, and entered a $100 million at-the-market facility. Revenues were $0.1 million versus $0.4 million in 2025; R&D expenses rose to $19.6 million, G&A was $10.6 million, and a $5.0 million intangible impairment was recorded. Net loss was $33.0 million, and cash, cash equivalents and debt securities totaled $88.0 million at June 30, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
Rhea-AI Summary

iBio (NASDAQ: IBIO) appointed endocrinologist Molly Carr, M.D. as Chief Medical Officer to lead global clinical strategy, medical affairs and regulatory initiatives as it advances its long-acting antibody pipeline for obesity and cardiometabolic diseases toward late-stage development.

According to iBio, Dr. Carr brings over 30 years of clinical, academic and biopharmaceutical experience, including senior roles at Eli Lilly, GlaxoSmithKline, CSL Behring and Wyeth, and leadership of Lilly’s insulin and glucagon franchise and the Phase 3 program for once-weekly insulin efsitora. iBio highlighted that her expertise aligns with its obesity, muscle biology and cardiometabolic programs, including IBIO-600 and IBIO-610. The company also granted Dr. Carr options to purchase 430,000 shares of common stock as an inducement award, with a $1.40 exercise price, 10-year term, time-based vesting through quarterly installments after a one-year cliff, and accelerated vesting upon certain change-in-control or involuntary termination events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.82%
Tags
none
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) reported preclinical obese non-human primate data for IBIO-610, a potential first-in-class Activin E antibody for obesity. A single dose reduced active Activin E by 98% at week 4 and 97% at week 8, with levels below assay limits.

Combined with semaglutide, IBIO-610 increased visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone, suggesting fat-selective weight loss potential and infrequent dosing. Full results will be presented at the 2026 EASD Annual Meeting in Milan.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
none
-
Rhea-AI Summary

iBio (NASDAQ: IBIO) announced participation in two upcoming healthcare investor conferences. CEO/CSO Martin Brenner and CFO Felipe Duran will present and hold investor meetings.

The events include the Jefferies Global Healthcare Conference on June 4, 2026, in New York and the Leerink Partners Therapeutics Forum on July 14–15, 2026, in Boston.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
none
Rhea-AI Summary

iBio (NASDAQ: IBIO) dosed the first participant in its Phase 1 trial of IBIO-600, becoming a clinical-stage company. IBIO-600 is a long-acting anti-myostatin/GDF11 monoclonal antibody being tested in adults with overweight and obesity for safety, tolerability, PK/PD, and exploratory body composition effects.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.88%
Tags

FAQ

What is the current stock price of iBio (IBIO)?

iBio (IBIO) last closed at $0.8001.

What is the market cap of iBio (IBIO)?

The market cap of iBio (IBIO) is approximately $56.4M.